Compare Marathon Petroleum Corp (MPC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs BIO-TECHNE Corp — how do they compare? Marathon Petroleum Corp trades at $401.71 (market cap $111.70B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Marathon Petroleum Corp is far larger — about 9.9× BIO-TECHNE Corp's market cap, and Marathon Petroleum Corp pays the higher dividend (1.01%). Which is the better fit depends on your goals.
| MPC | TECH | |
|---|---|---|
Market Cap | $111.70B | $11.34B |
Sector | Energy | Health |
52-Week High | $399.44 | $72.48 |
52-Week Low | $162.63 | $43.31 |
Enterprise Value | $138.23B | $11.36B |
Dividend Yield | 1.01% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $397.77, up 2.28% today and near its 52-week high, with a bullish technical outlook from moving averages and strong momentum. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $17.73 surpassing the $14.27 forecast. Valuation ratios appear attractive with a P/E of 13.79 and P/S of 0.77, while profitability metrics like a 47.9% ROE highlight efficient capital use. Recent news emphasizes refinery investments and benefits from geopolitical energy risks.
The outlook for MPC is positive, driven by robust earnings performance, favorable refining margins, and strong analyst support with 26 buy ratings. Key opportunities include high-return projects and cash flow growth, with 2026 net income projected at $8.6B. Risks involve exposure to oil price volatility, cyclical demand, and rising debt-to-asset ratios, which increased to 42.59% in 2025. Investors should weigh solid fundamentals against sector-specific headwinds.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
